Pharmaceuticals
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.
This page shows you the most recent publications within this specialty of the MedWorm directory. This is page number 27.
Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Nashville, Tenn., Oct. 29 (HSMN NewsFeed) -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX ) and Phebra Pty Ltd., an Australian-based specialty pharmaceutical company, today announced they have entered into an exclusive partnership for the commercializat... BiopharmaceuticalsCumberland Pharmaceuticals, Phebra, Caldolor, ibuprofen
Source: HSMN NewsFeed - October 29, 2009 Category: Pharmaceuticals Source Type: news
High-Resolution Breast PET Improves Breast Cancer DetectionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Positron emission mammography (PEM) improves breast cancer detection.
PEM significantly improves ability to differentiate between benign and cancerous lesions.
Combination of PEM and breast MRI dramatically increased number of suspicious lesions foun... Devices, RadiologyNaviscan, Positron Emission Mammography, imaging
Source: HSMN NewsFeed - October 29, 2009 Category: Pharmaceuticals Source Type: news
28.10.09: Stock: Voting RightsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Stock: Voting RightsNew: Information from Capital Research and Management CompanyLink to websiteAll changes
Source: Bayer IR Newsfeed: New on this site - October 29, 2009 Category: Pharmaceuticals Source Type: news
Photo Release -- Competitive Technologies' Medical Device Receives Innovation AwardEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
FAIRFIELD, Conn., Oct. 29, 2009 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (NYSE Amex:CTT) announced today that it received a silver CQIA Innovation Prize for its Calmare Therapy Treatment*, pain therapy medical device. The award was presented to John B. Nano, CTT's Chairman, President and CEO, by the Connecticut Quality Improvement Award Partnership, Inc. at its 22nd Annual Conference on Quality and Innovation held on October 23, 2009, in Westbrook, CT.
Source: Medical News (via PRIMEZONE) - October 29, 2009 Category: Pharmaceuticals Source Type: news
Clarient to Release 2009 Third Quarter Financial Results on Tuesday, November 3rdEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
ALISO VIEJO, Calif., Oct. 29, 2009 (GLOBE NEWSWIRE) -- Clarient, Inc. (Nasdaq:CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it will report its financial results for the third quarter ended September 30, 2009 after the stock market closes on Tuesday, November 3rd.
Source: Medical News (via PRIMEZONE) - October 29, 2009 Category: Pharmaceuticals Source Type: news
Environmental Tectonics Corporation's BioMedical Division Announces Multiple Hyperbaric Chamber SalesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SOUTHAMPTON, Pa., Oct. 29 (HSMN NewsFeed) -- Environmental Tectonics Corporation's (OTC Bulletin Board: ETCC ; "ETC" or the "Company") BioMedical Division today announced a record month for sales of their Baramed monoplace chambers. D... Devices, Wound CareEnvironmental Tectonics, hyperbaric oxygen, hyperbaric chamber
Source: HSMN NewsFeed - October 29, 2009 Category: Pharmaceuticals Source Type: news
ASTRO Presentations Highlight Role of TomoTherapy(R) Technology in Combined Modality Approach to Treating CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
New Studies Explore Use of Helical TomoTherapy(SM) Treatments for Indications Previously Not Treated With Radiation Therapy
MADISON, WI--(HSMN NewsFeed) - TomoTherapy Incorporated (NASDAQ:TOMO ) announced today that several clinical presentations at the... Devices, OncologyTomoTherapy, Hi-Art, radiotherapy
Source: HSMN NewsFeed - October 29, 2009 Category: Pharmaceuticals Source Type: news
House Democrats Unveil Health BillEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
House health-care legislation includes a compromise version of a public insurance option and carries an overall cost of $894 billion over 10 years.
Source: WSJ.com: Health - October 29, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
University of Virginia Cancer Center Treats First Patients With New TomoTherapy(R) Radiation Delivery ModeEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
TomoDirect(TM) Mode Brings Discrete-Angle Delivery Efficiency to TomoTherapy's Advanced Radiation Therapy Platform
MADISON, WI - (HSMN NewsFeed) - TomoTherapy Incorporated (NASDAQ:TOMO ) announced today that the first patients are now being treated with... Devices, OncologyTomoTherapy, TomoDirect, radiotherapy
Source: HSMN NewsFeed - October 29, 2009 Category: Pharmaceuticals Source Type: news
NeoPharm Names Dr. Aquilur Rahman as President and CEOEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
LAKE BLUFF, Ill.--(HSMN NewsFeed)--NeoPharm, Inc. (Other OTC: NEOL.PK ) today announced the appointment of Dr. Aquilur Rahman to the position of President and CEO of the Company, succeeding Laurence P. Birch, who is stepping down as President and CEO to pu... Biopharmaceuticals, PersonnelNeoPharm
Source: HSMN NewsFeed - October 29, 2009 Category: Pharmaceuticals Source Type: news
Genta Announces Top-Line Results of AGENDA Phase 3 Trial of Genasense(R) in Patients with Advanced MelanomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
BERKELEY HEIGHTS, N.J.--(HSMN NewsFeed)--Genta Incorporated (OTCBB: GETA ) today announced top-line results from AGENDA, the Companys Phase 3 trial of Genasense(R) (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, d... Biopharmaceuticals, OncologyGenta , Genasense, oblimersen, melanoma
Source: HSMN NewsFeed - October 29, 2009 Category: Pharmaceuticals Source Type: news
FDA Grants Emergency Use Authorization of the Prodesse ProFlu-ST(TM)Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Assay Detects 2009 H1N1 Influenza Virus, Aided by an Algorithm that Relies on Seasonal Influenza A/H1 Virus and Seasonal Influenza A/H3 Virus Results
SAN DIEGO, Oct. 29 (HSMN NewsFeed) -- Gen-Probe Incorporated (Nasdaq: GPRO ) today announced that the... Diagnostics, FDAGen-Probe, Prodesse ProFlu-ST, H1N1, influenza
Source: HSMN NewsFeed - October 29, 2009 Category: Pharmaceuticals Source Type: news
Activaero Closes a 10.7 Million ($16 million) Series A FinancingEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
GEMUENDEN, Germany & DUBLIN, Ohio--(HSMN NewsFeed)--Activaero GmbH, the leading company in the field of controlled breathing technologies for inhaled therapeutic agents, announced today the closing of a Series A financing totalling 10.7 Million ($16 mill... Devices, Drug Delivery, Venture CapitalActivaero, pulmonary delivery
Source: HSMN NewsFeed - October 29, 2009 Category: Pharmaceuticals Source Type: news
Novo Nordisk Interim Financial Report for nine months ending 30 September 2009Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Novo Nordisk increased operating profit by 30% in the first nine
months of 2009
Sales increased by 15% in Danish kroner and by 11% in local
currencies.
o Sales of modern insulins increased by 28% (24% in local
currencies).
o...
Source: Drugs.com - Pharma News - October 29, 2009 Category: Pharmaceuticals Source Type: news
AstraZeneca PLC Third Quarter & Nine Months Results 2009Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
LONDON, Oct. 29. 2009--Strong business
performance has been driven by good operating execution bolstered
by revenue upsides from Toprol-XL and H1N1 vaccine sales. Core EPS
target for the year has been increased and progress has been made
on the...
Source: Drugs.com - Pharma News - October 29, 2009 Category: Pharmaceuticals Source Type: news
Ipsen Announces the Launch of Dysport(R) (abobotulinumtoxinA) in the United States for the Treatment of Cervical DystoniaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Dysport(R) represents the first new botulinum toxin type A treatment option in eight years to reach the U.S. market place
PARIS--(HSMN NewsFeed)--Ipsen (Paris: IPN ), an innovation-driven global specialty pharmaceutical group, today announced that Dyspo... BiopharmaceuticalsIpsen, Dysport, abobotulinumtoxinA, cervical dystonia
Source: HSMN NewsFeed - October 29, 2009 Category: Pharmaceuticals Source Type: news
Plex Systems: Plex Systems CEO and President to Moderate Product Diversification Panel at MichBio Conference Nov. 3 - 4, 2009, Kalamazoo, Mich.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
AUBURN HILLS, MI (MARKET WIRE) Plex Systems, Inc., provider of the No. 1 rated ERP software for manufacturers including medical device manufacturers, announced today that CEO and President Mark Symonds will be moderating a product diversification panel discussion at the MichBio Expo 2009 to be held at the Radisson Plaza Hotel in Kalamazoo, Michigan November 3 - 4, 2009. Plex Systems will also exhibit at the event.
Source: Market Wire - Pharmaceuticals and Biotech - October 29, 2009 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech Computers and Software Source Type: news
CNS Response: Results of Landmark Depression Efficacy Study to Be Discussed by CNS Response in a Conference Call and Web ConferenceEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
COSTA MESA, CA (MARKET WIRE) CNS Response, Inc. (OTCBB: CNSO) today announced that CEO George Carpenter will be conducting a conference call and simultaneous web conference to discuss top-line study results in a 12-week trial for patients with depression treatment failure on Tuesday, November 3, at 8:00 a.m. Pacific (PST), 11:00 a.m. Eastern (EST). Joining Mr. Carpenter will be CNS Response President and CMO Daniel Hoffman, M.D., and Charles DeBattista, M.D., Stanford University School of Medicine.
Source: Market Wire - Pharmaceuticals and Biotech - October 29, 2009 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech Medical and Healthcare CNSO Source Type: news
UGA prof wins $660K stimulus grantEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The University of Georgia professor and Georgia Research Alliance Eminent Scholar of Molecular Biology Stephen Dalton got a $600,000 federal stimulus grant to accelerate research into a type of stem cell that can turn into virtually any cell type, the university reported Thursday.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 29, 2009 Category: Pharmaceuticals Source Type: journals
House Compromises on Public OptionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
House Democrats signaled that the health-care bill will include a government insurance plan that would negotiate payment rates with hospitals and doctors instead of having them tied to Medicare rates.
Source: WSJ.com: Health - October 29, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
Allergan Reports Third Quarter 2009 Operating ResultsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Board of Directors Declares
Third Quarter Dividend
IRVINE, Calif.--(BUSINESS WIRE)--Oct 29, 2009 - Allergan, Inc.
(NYSE: AGN) today announced operating results for the quarter ended
September 30, 2009. Allergan also announced that its Board...
Source: Drugs.com - Pharma News - October 29, 2009 Category: Pharmaceuticals Source Type: news
Mylan Reports Third Quarter Adjusted Diluted EPS of $0.32Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Mylan Raises 2009 Adjusted Diluted EPS Guidance Range to
$1.24 - $1.28 Solid Operational Performance and Strong Cash Flow
Continue to Build Earnings Momentum
PITTSBURGH, Oct. 29 /PRNewswire-FirstCall/ -- Mylan Inc.
(NASDAQ:MYL)
today...
Source: Drugs.com - Pharma News - October 29, 2009 Category: Pharmaceuticals Source Type: news
Kansas Board of Healing Arts names interim headEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The Kansas Board of Healing Arts has appointed one of its staff attorneys to be acting executive director.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 29, 2009 Category: Pharmaceuticals Source Type: journals
AstraZeneca: Third Quarter and Nine Months Results 2009Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
STOCKHOLM--(BUSINESS WIRE)--Oct 29, 2009 - AstraZeneca (STO:AZN)
(LSE:AZN)
Third quarter revenue increased by 10 percent at constant
exchange rates (CER) to $8,200 million.
-US sales of Toprol-XL, benefiting from withdrawal of generic
products,...
Source: Drugs.com - Pharma News - October 29, 2009 Category: Pharmaceuticals Source Type: news
Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug ApplicationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conference Call Scheduled for 8:30 a.m. EDT on October 29, 2009
RICHMOND, Calif., Oct. 29 (HSMN NewsFeed) -- Transcept Pharmaceuticals (Nasdaq: TSPT ) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter r... Biopharmaceuticals, FDATranscept Pharmaceuticals, Intermezzo, zolpidem, insomnia
Source: HSMN NewsFeed - October 29, 2009 Category: Pharmaceuticals Source Type: news
Health Sciences Group Engages Into Conversation With Medical Marijuana, Inc. About Consulting / Co-R&D VentureEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
INDIAN HARBOUR BEACH, Fla., Oct. 29, 2009 (GLOBE NEWSWIRE) -- Health Sciences Group, Inc. (Pink Sheets:HESG) is proud to announce that its CEO Thomas Gaffney has engaged in preliminary conversations with Bruce Perlowin, Founder, Chairman, & CEO of Medical Marijuana, Inc. (MJNA), about the possibilities of the companies merging co- research and development and consulting services. "These conversations were preliminary in nature. I look forward to more discussions with Mr. Perlowin about the services Medical Marijuana, Inc. provides and how we can work together to grow our companies and increase shareholder value on both sides."
Source: Medical News (via PRIMEZONE) - October 29, 2009 Category: Pharmaceuticals Source Type: news
Fear and Loathing in Washington, DCEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
John Mack, Editor of Pharma Marketing News, will make a presentation in front of the DDMAC at the November, 2009, public hearing on Promotion of Food and Drug Administration-Regulated Medical Products Using the Internet and Social Media Tools.
Source: Pharma Marketing News - October 29, 2009 Category: Pharmaceuticals Source Type: info
Risk Mitigation and Its Impact on Pharma MarketingEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
This article summarizes ParagonRx's ideas about how to develop a REMS that can be a win-win-win situation for you, your product, and the patient.
Source: Pharma Marketing News - October 29, 2009 Category: Pharmaceuticals Source Type: info
Pharmaceutical Market Access 2010Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
This article addresses that question.
Source: Pharma Marketing News - October 29, 2009 Category: Pharmaceuticals Source Type: info
Social Media Adverse Event Reporting Safe HarborsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
This article presents ideas for regulatory 'safe harbors' under which pharmaceutical companies would be relieved of the responsibility of monitoring social media for adverse events. Includes a detailed summary of responses to the survey "FDA Regulation of Drug & Device Promotion via the Internet & Social Media" regarding social media adverse event monitoring, processing, challenges, and uncertainties.
Source: Pharma Marketing News - October 29, 2009 Category: Pharmaceuticals Source Type: info
Genta Announces Top-Line Results of AGENDA Phase 3 Trial of Genasense in Patients with Advanced MelanomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
[webcast]
BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Oct 29, 2009 - Genta
Incorporated (OTCBB: GETA) today announced top-line results from
AGENDA, the Company's Phase 3 trial of Genasense®
(oblimersen sodium) Injection in patients with advanced...
Source: Drugs.com - Clinical Trials - October 29, 2009 Category: Pharmaceuticals Source Type: clinical trials
Rockwell Medical Completes SFP Phase IIb Clinical StudyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
WIXOM, Mich., Oct. 29, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that the last patient has completed the Phase IIb clinical study to investigate Soluble Ferric Pyrophosphate (SFP), the Company's proprietary investigational iron maintenance therapy.
Source: Medical News (via PRIMEZONE) - October 29, 2009 Category: Pharmaceuticals Source Type: news
CAS Medical Systems, Inc. Announces Third Quarter and Year-to-Date 2009 Earnings Release Date and Conference Call InformationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
BRANFORD, Conn., Oct. 29, 2009 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (Nasdaq:CASM) today announced that the Company will release third quarter and year-to-date results for the period ended September 30, 2009 on Thursday, November 5, 2009 before the market opens. The Company will host a conference call that same day at 10:00 a.m. Eastern Time. Participants on the call will be Andrew Kersey, President and CEO, and Jeffery Baird, CFO.
Source: Medical News (via PRIMEZONE) - October 29, 2009 Category: Pharmaceuticals Source Type: news
Transcept Pharmaceuticals Receives Complete Response Letter From FDA On Intermezzo® New Drug ApplicationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Transcept Pharmaceuticals (Nasdaq: TSPT) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet).
Source: Pharmaceutical Online News - October 29, 2009 Category: Pharmaceuticals Source Type: news
P&G First Quarter Sales and EPS Exceed ExpectationsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CINCINNATI, Oct. 29, 2009 /PRNewswire-FirstCall/ -- The Procter
& Gamble Company (NYSE: PG) reported net sales of $19.8 billion
for the July - September quarter which exceeded the Company's
guidance. Organic sales growth was up two percent...
Source: Drugs.com - Pharma News - October 29, 2009 Category: Pharmaceuticals Source Type: news
C. K. Cooper & Company Initiates Coverage of ICU Medical Inc.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
IRVINE, Calif., Oct. 29, 2009 (GLOBE NEWSWIRE) -- C. K. Cooper & Company, an independent, full-service investment bank, headquartered in Irvine, Calif. announced today that it has initiated coverage of ICU Medical Inc. (Nasdaq:ICUI).
Source: Medical News (via PRIMEZONE) - October 29, 2009 Category: Pharmaceuticals Source Type: news
Alcon Posts 5.9 Percent Sales Growth for Third QuarterEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Third Quarter
Highlights
Organic sales growth was 9.0
percent
Operating profit rose 17.0
percent to $578 million
Sales of advanced technology
intraocular lenses increased 34.2 percent
Management raises outlook for
full year earnings per...
Source: Drugs.com - Pharma News - October 29, 2009 Category: Pharmaceuticals Source Type: news
Orchid Cellmark Reports Third Quarter 2009 Financial ResultsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
PRINCETON, N.J., Oct. 29, 2009 (GLOBE NEWSWIRE) -- Orchid Cellmark Inc. (Nasdaq:ORCH), a leading international provider of identity DNA testing services, today reported its financial results for the third quarter of 2009.
Source: Medical News (via PRIMEZONE) - October 29, 2009 Category: Pharmaceuticals Source Type: news
Aetna Earnings Rise 18%Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Aetna's profit rose 18% on better returns from its investments, while costs related to the H1N1 flu hurt margins at its commercial plans.
Source: WSJ.com: Health - October 29, 2009 Category: Pharmaceuticals Tags: PAID Source Type: news
IBM to Drop Co-Pay for Some Doctor VisitsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
In an unusual bid to cut health-care costs, IBM plans to stop requiring $20 co-payments by employees when they visit primary-care physicians.
Source: WSJ.com: Health - October 29, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
Aurobindo gets South African regulator's nod to market drugsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Drug firm, Aurobindo Pharma today said it has received approval from the South African regulator to manufacture and market two drugs in that country.
Source: The Economic Times Healthcare and Biotech News - October 29, 2009 Category: Pharmaceuticals Source Type: news
First Phase III clinical trial of Roche's weekly taspoglutide meets primary end-point of change in HbA1cEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Roche today announced that headline results from its Phase III study, T-emerge 2 (subcutaneous weekly taspoglutide versus subcutaneous twice-daily exenatide, as add-on to metformin, a thiazolidinedione [TZD], or metformin and a TZD), showed that the trial met its primary endpoint of change in HbA1c. Superiority versus exenatide was demonstrated.
Source: Roche Investor Update - October 29, 2009 Category: Pharmaceuticals Source Type: organizations
First Phase III clinical trial of Roche`s weekly taspoglutide meets primary end-point of change in HbA1cEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Roche today announced that headline results from its Phase III study, T-emerge 2 (subcutaneous weekly taspoglutide versus subcutaneous twice-daily exenatide, as add-on to metformin, a thiazolidinedione [TZD], or metformin and a TZD), showed that the trial met its primary endpoint of change in HbA1c. Superiority versus exenatide was demonstrated.
Source: Roche Investor Update - October 29, 2009 Category: Pharmaceuticals Source Type: organizations
Malvern Instruments And Kaiser Optical Systems Collaborate To Develop An Advanced Range Of Raman MicroscopesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Materials characterization company Malvern Instruments (Malvern, Worcs, UK) and Kaiser Optical Systems (Ann Arbor, MI, USA), a leading supplier of Raman analyzers and components for spectroscopy, announce a development collaboration that will enhance the product portfolios of both companies.
Source: Pharmaceutical Online News - October 29, 2009 Category: Pharmaceuticals Source Type: news
FrieslandCampina Domo Name Change Process Aims To Ensure A Seamless Transition For American CustomersEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
As FrieslandCampina Domo implements its entity change process, the operating company's primary goal is to ensure a smooth and seamless transition for its customers.
Source: Pharmaceutical Online News - October 29, 2009 Category: Pharmaceuticals Source Type: news
Abbott Receives Sustainability Award for Continued Efforts to Protect the Environment in IllinoisEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Abbott.com - October 29, 2009 Category: Pharmaceuticals Source Type: organizations
SP Industries' Freeze Dryers Get GreenerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SP Industries Inc. has announced that its VirTis Genesis 25 and 35 XL Freeze Drying Systems, now featuring proprietary auto-cascade refrigeration technology, can achieve low freeze drying temperatures while reducing operational energy consumption by 30 to 40% compared to two compressor cascade systems.
Source: Pharmaceutical Online News - October 29, 2009 Category: Pharmaceuticals Source Type: news
Bantam™ Magnet And Magna-Bar From Eriez® Provide A Solution For Automation And Separation ApplicationsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Eriez® offers two permanent, non-electric bar magnets to meet many automation, separation and holding requirements. "These powerful and economical magnets are ideal for a wide variety of applications," said John Mackowski, Product Manager.
Source: Pharmaceutical Online News - October 29, 2009 Category: Pharmaceuticals Source Type: news
